Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Operating Income (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Operating Income data on record, last reported at -$39.9 million in Q4 2022.

  • For Q4 2022, Operating Income fell 132.93% year-over-year to -$39.9 million; the TTM value through Dec 2022 reached -$130.6 million, down 194.42%, while the annual FY2025 figure was -$180.9 million, 6.25% up from the prior year.
  • Operating Income reached -$39.9 million in Q4 2022 per AVIR's latest filing, down from -$16.3 million in the prior quarter.
  • Across five years, Operating Income topped out at $121.2 million in Q4 2021 and bottomed at -$42.2 million in Q1 2022.
  • Average Operating Income over 3 years is -$275333.3, with a median of -$13.1 million recorded in 2020.
  • Peak YoY movement for Operating Income: soared 857.85% in 2021, then crashed 471.76% in 2022.
  • A 3-year view of Operating Income shows it stood at $20.6 million in 2020, then soared by 486.92% to $121.2 million in 2021, then crashed by 132.93% to -$39.9 million in 2022.
  • Per Business Quant database, its latest 3 readings for Operating Income were -$39.9 million in Q4 2022, -$16.3 million in Q3 2022, and -$32.3 million in Q2 2022.